Global Regenerative Medicine Market By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III); By Offerings (Cell Therapy – Autologous, Allogeneic, Both, Gene Therapy, Tissue Engineering and Biomaterials, Cellular Scaffold, Others); By Therapeutic Areas (Autoimmune, Oncology, Cardiovascular, Dermatology, Musculoskeletal, Ophthalmology, Neurology, Wound Healing, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1290 | Category : Healthcare | Published Date : October, 2022 | Pages : 402 | Format :PDF

Industry Trends

Global regenerative medicine market is expected to reach US$ 48.3 Bn by 2030, growing at an estimated CAGR of 25% over the forecast period. The amount of progress medical science has made is insane. The treatment of those diseases which was not possible yesteryear can be done easily in today’s time. Rampant research in the field of medical research is the reason why healthcare sector is growing. Regenerative medicine is being seen as a great alternative by the medical fraternity. Regenerative medicine primarily works by replacing tissue or organs that have been damaged through disease, trauma, or any type of congenital issues. Regenerative medicine happens to a newer way of treatment that is a fusion of biology, computer science, medicine, genetics, chemistry, engineering, robotics and medicine to find remedy to couple of the most challenging issues related to medical science faced by the mankind. Regenerative medicines enhance our body’s abilities to recover itself. It helps our body to restore structure and function of tissues and organs that are damaged. The medical experts are working day and night in creation of solutions for organs that are damaged permanently. The global regenerative medicine market is growing rampantly due to need of treatment for diseases which cannot be treated.

The global regenerative medicine market witnessed tremendous growth during the COVID-19 pandemic. The life-threatening virus claimed lives of millions across the planet and regenerative medicines were seen as an alternative in help body battle against it.

By Clinical Trial Phase

On the basis of clinical trial phase, the global regenerative medicine market has been divided into preclinical, phase I, phase II, and phase III. The preclinical segment accounts for majority of money made by this market. The efficacy of any drug or medicine is determine usually in the preclinical phase before it is tested on humans or any living species. The primary objective of preclinical studies are to understand a beginning, safe dose for initial human study and assess potential quality of the product, which usually is inclusive of newer medical devices, drugs to be prescribed, along with diagnostics.

Global Regenerative Medicine Market Revenue & Forecast, (US$ Million), 2022 – 2030

Offerings Outlook

On the basis of offerings, the global regenerative medicine market has been categorised into cell therapy, gene therapy, tissue engineering and biomaterials, cellular scaffold, and others. The cell therapy segment is further segmented into autologous, allogenic and both. The autologous segment mints majority of money for this market. Also the tissue engineering and biomaterials segment generates major amount of revenue for this market. Treating a damaged tissue is the major motive of regenerative medicines.

Therapeutic Areas Outlook

The therapeutic areas segment of the global regenerative medicine market has been divided into autoimmune, oncology, cardiovascular, dermatology, musculoskeletal, ophthalmology, neurology, wound healing and others. The musculoskeletal segment has been dominating in terms of market share for this market. The regenerative medicines are extensively used in the treatment of damaged bones, muscles, ligaments or joints. The changes of these parts being damaged due to any injury or ailment are high, and this is where the regenerative medicines are proving helpful.

Region Outlook

On the basis of region, the global regenerative medicine market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America ranks at the top in terms of accounting for maximum sales generated by this market. Presence of top medical research companies and higher spending capacity of the patients helps this market grow rampantly in the region.

Competitive Landscape

The report provides both, qualitative and quantitative research of global regenerative medicine market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the major players operating in the global regenerative medicine market are listed below:

3M
ALLERGAN
Amgen, Inc.
Athersys, Inc.
Integra LifeSciences
Isto Biologics
Medtronic
Novartis AG
Organogenesis Inc.
Sartorius AG
Spark Therapeutics, Inc.
Takeda Pharmaceutical Company Limited.
XCELL BIOLOGIX
Zimmer Biomet
Other Market Participants

Global Regenerative Medicine Market

By Clinical Trial Phase

Preclinical
Phase I
Phase II
Phase III

By Offerings

Cell Therapy
- Autologous
- Allogenic
- Both
Gene Therapy
Tissue Engineering and Biomaterials
Cellular Scaffold
Others

By Therapeutics Areas

Autoimmune
Oncology
Cardiovascular
Dermatology
Musculoskeletal
Ophthalmology
Neurology
Wound Healing
Others

By Region

North America
- U.S
- Canada
- Mexico
- Rest of North America
Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
  - Denmark
  - Finland
  - Iceland
  - Sweden
  - Norway
- Benelux Union
  - Belgium
  - The Netherlands
  - Luxembourg
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
  - Indonesia
  - Thailand
  - Malaysia
  - Singapore
  - Rest of Southeast Asia
- Rest of Asia Pacific
Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America

Table of Contents

1. Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2020

1.2.2. Base Year: 2021

1.2.3. Forecast Years: 2022 - 2030

2. Key Target Audiences

3. Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4. Recommendations and Insights from AMIâ€™s Perspective**

5. Holistic Overview ofÂ Regenerative MedicineÂ Market

6. Market Synopsis:Â Â Regenerative MedicineÂ Market

7. Â Regenerative MedicineÂ Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends inÂ Regenerative MedicineÂ Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators:Â Regenerative MedicineÂ Market

7.6. Porterâ€™s Five Force Analysis

7.7. Impact of Covid-19 onÂ Regenerative MedicineÂ Market

7.8. PESTEL Analysis

8. GlobalÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

8.1. Overview

8.1.1. GlobalÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

8.2. GlobalÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

8.2.1. Preclinical

8.2.1.1. Definition

8.2.1.2. Market Estimation and Penetration, 2015 - 2021

8.2.1.3. Market Forecast, 2022 - 2030

8.2.1.4. Compound Annual Growth Rate (CAGR)

8.2.1.5. Regional Bifurcation

8.2.1.5.1. North America

8.2.1.5.1.1. Market Estimation, 2015 - 2021

8.2.1.5.1.2. Market Forecast, 2022 - 2030

8.2.1.5.2. Europe

8.2.1.5.2.1. Market Estimation, 2015 - 2021

8.2.1.5.2.2. Market Forecast, 2022 - 2030

8.2.1.5.3. Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 - 2021

8.2.1.5.3.2. Market Forecast, 2022 - 2030

8.2.1.5.4. Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 - 2021

8.2.1.5.4.2. Market Forecast, 2022 - 2030

8.2.1.5.5. Latin America

8.2.1.5.5.1. Market Estimation, 2015 - 2021

8.2.1.5.5.2. Market Forecast, 2022 - 2030

8.2.2. Phase I

8.2.2.1. Definition

8.2.2.2. Market Estimation and Penetration, 2015 - 2021

8.2.2.3. Market Forecast, 2022 - 2030

8.2.2.4. Compound Annual Growth Rate (CAGR)

8.2.2.5. Regional Bifurcation

8.2.2.5.1. North America

8.2.2.5.1.1. Market Estimation, 2015 - 2021

8.2.2.5.1.2. Market Forecast, 2022 - 2030

8.2.2.5.2. Europe

8.2.2.5.2.1. Market Estimation, 2015 - 2021

8.2.2.5.2.2. Market Forecast, 2022 - 2030

8.2.2.5.3. Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 - 2021

8.2.2.5.3.2. Market Forecast, 2022 - 2030

8.2.2.5.4. Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 - 2021

8.2.2.5.4.2. Market Forecast, 2022 - 2030

8.2.2.5.5. Latin America

8.2.2.5.5.1. Market Estimation, 2015 - 2021

8.2.2.5.5.2. Market Forecast, 2022 - 2030

8.2.3. Phase II

8.2.3.1. Definition

8.2.3.2. Market Estimation and Penetration, 2015 - 2021

8.2.3.3. Market Forecast, 2022 - 2030

8.2.3.4. Compound Annual Growth Rate (CAGR)

8.2.3.5. Regional Bifurcation

8.2.3.5.1. North America

8.2.3.5.1.1. Market Estimation, 2015 - 2021

8.2.3.5.1.2. Market Forecast, 2022 - 2030

8.2.3.5.2. Europe

8.2.3.5.2.1. Market Estimation, 2015 - 2021

8.2.3.5.2.2. Market Forecast, 2022 - 2030

8.2.3.5.3. Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 - 2021

8.2.3.5.3.2. Market Forecast, 2022 - 2030

8.2.3.5.4. Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 - 2021

8.2.3.5.4.2. Market Forecast, 2022 - 2030

8.2.3.5.5. Latin America

8.2.3.5.5.1. Market Estimation, 2015 - 2021

8.2.3.5.5.2. Market Forecast, 2022 - 2030

8.2.4. Phase III

8.2.4.1. Definition

8.2.4.2. Market Estimation and Penetration, 2015 - 2021

8.2.4.3. Market Forecast, 2022 - 2030

8.2.4.4. Compound Annual Growth Rate (CAGR)

8.2.4.5. Regional Bifurcation

8.2.4.5.1. North America

8.2.4.5.1.1. Market Estimation, 2015 - 2021

8.2.4.5.1.2. Market Forecast, 2022 - 2030

8.2.4.5.2. Europe

8.2.4.5.2.1. Market Estimation, 2015 - 2021

8.2.4.5.2.2. Market Forecast, 2022 - 2030

8.2.4.5.3. Asia Pacific

8.2.4.5.3.1. Market Estimation, 2015 - 2021

8.2.4.5.3.2. Market Forecast, 2022 - 2030

8.2.4.5.4. Middle East and Africa

8.2.4.5.4.1. Market Estimation, 2015 - 2021

8.2.4.5.4.2. Market Forecast, 2022 - 2030

8.2.4.5.5. Latin America

8.2.4.5.5.1. Market Estimation, 2015 - 2021

8.2.4.5.5.2. Market Forecast, 2022 - 2030

8.3. Key Segment for Channeling Investments

8.3.1. By Clinical Trial Phase

9. GlobalÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

9.1. Overview

9.2. GlobalÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

9.2.1. Cell therapy (Definition, Market Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Autologous , Allogeneic , Both )

9.2.1.1. Autologous

9.2.1.2. Allogeneic

9.2.1.3. Both

9.2.2. Gene therapy

9.2.2.1. Definition

9.2.2.2. Market Estimation and Penetration, 2015 - 2021

9.2.2.3. Market Forecast, 2022 - 2030

9.2.2.4. Compound Annual Growth Rate (CAGR)

9.2.2.5. Regional Bifurcation

9.2.2.5.1. North America

9.2.2.5.1.1. Market Estimation, 2015 - 2021

9.2.2.5.1.2. Market Forecast, 2022 - 2030

9.2.2.5.2. Europe

9.2.2.5.2.1. Market Estimation, 2015 - 2021

9.2.2.5.2.2. Market Forecast, 2022 - 2030

9.2.2.5.3. Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 - 2021

9.2.2.5.3.2. Market Forecast, 2022 - 2030

9.2.2.5.4. Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 - 2021

9.2.2.5.4.2. Market Forecast, 2022 - 2030

9.2.2.5.5. Latin America

9.2.2.5.5.1. Market Estimation, 2015 - 2021

9.2.2.5.5.2. Market Forecast, 2022 - 2030

9.2.3. Tissue Engineering and Biomaterials

9.2.3.1. Definition

9.2.3.2. Market Estimation and Penetration, 2015 - 2021

9.2.3.3. Market Forecast, 2022 - 2030

9.2.3.4. Compound Annual Growth Rate (CAGR)

9.2.3.5. Regional Bifurcation

9.2.3.5.1. North America

9.2.3.5.1.1. Market Estimation, 2015 - 2021

9.2.3.5.1.2. Market Forecast, 2022 - 2030

9.2.3.5.2. Europe

9.2.3.5.2.1. Market Estimation, 2015 - 2021

9.2.3.5.2.2. Market Forecast, 2022 - 2030

9.2.3.5.3. Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 - 2021

9.2.3.5.3.2. Market Forecast, 2022 - 2030

9.2.3.5.4. Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 - 2021

9.2.3.5.4.2. Market Forecast, 2022 - 2030

9.2.3.5.5. Latin America

9.2.3.5.5.1. Market Estimation, 2015 - 2021

9.2.3.5.5.2. Market Forecast, 2022 - 2030

9.2.4. Cellular Scaffold

9.2.4.1. Definition

9.2.4.2. Market Estimation and Penetration, 2015 - 2021

9.2.4.3. Market Forecast, 2022 - 2030

9.2.4.4. Compound Annual Growth Rate (CAGR)

9.2.4.5. Regional Bifurcation

9.2.4.5.1. North America

9.2.4.5.1.1. Market Estimation, 2015 - 2021

9.2.4.5.1.2. Market Forecast, 2022 - 2030

9.2.4.5.2. Europe

9.2.4.5.2.1. Market Estimation, 2015 - 2021

9.2.4.5.2.2. Market Forecast, 2022 - 2030

9.2.4.5.3. Asia Pacific

9.2.4.5.3.1. Market Estimation, 2015 - 2021

9.2.4.5.3.2. Market Forecast, 2022 - 2030

9.2.4.5.4. Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2015 - 2021

9.2.4.5.4.2. Market Forecast, 2022 - 2030

9.2.4.5.5. Latin America

9.2.4.5.5.1. Market Estimation, 2015 - 2021

9.2.4.5.5.2. Market Forecast, 2022 - 2030

9.2.5. Others

9.2.5.1. Definition

9.2.5.2. Market Estimation and Penetration, 2015 - 2021

9.2.5.3. Market Forecast, 2022 - 2030

9.2.5.4. Compound Annual Growth Rate (CAGR)

9.2.5.5. Regional Bifurcation

9.2.5.5.1. North America

9.2.5.5.1.1. Market Estimation, 2015 - 2021

9.2.5.5.1.2. Market Forecast, 2022 - 2030

9.2.5.5.2. Europe

9.2.5.5.2.1. Market Estimation, 2015 - 2021

9.2.5.5.2.2. Market Forecast, 2022 - 2030

9.2.5.5.3. Asia Pacific

9.2.5.5.3.1. Market Estimation, 2015 - 2021

9.2.5.5.3.2. Market Forecast, 2022 - 2030

9.2.5.5.4. Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2015 - 2021

9.2.5.5.4.2. Market Forecast, 2022 - 2030

9.2.5.5.5. Latin America

9.2.5.5.5.1. Market Estimation, 2015 - 2021

9.2.5.5.5.2. Market Forecast, 2022 - 2030

9.3. Key Segment for Channeling Investments

9.3.1. By Offerings

10. GlobalÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

10.1. Overview

10.2. GlobalÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

10.2.1. Autoimmune

10.2.1.1. Definition

10.2.1.2. Market Estimation and Penetration, 2015 - 2021

10.2.1.3. Market Forecast, 2022 - 2030

10.2.1.4. Compound Annual Growth Rate (CAGR)

10.2.1.5. Regional Bifurcation

10.2.1.5.1. North America

10.2.1.5.1.1. Market Estimation, 2015 - 2021

10.2.1.5.1.2. Market Forecast, 2022 - 2030

10.2.1.5.2. Europe

10.2.1.5.2.1. Market Estimation, 2015 - 2021

10.2.1.5.2.2. Market Forecast, 2022 - 2030

10.2.1.5.3. Asia Pacific

10.2.1.5.3.1. Market Estimation, 2015 - 2021

10.2.1.5.3.2. Market Forecast, 2022 - 2030

10.2.1.5.4. Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2015 - 2021

10.2.1.5.4.2. Market Forecast, 2022 - 2030

10.2.1.5.5. Latin America

10.2.1.5.5.1. Market Estimation, 2015 - 2021

10.2.1.5.5.2. Market Forecast, 2022 - 2030

10.2.2. Oncology

10.2.2.1. Definition

10.2.2.2. Market Estimation and Penetration, 2015 - 2021

10.2.2.3. Market Forecast, 2022 - 2030

10.2.2.4. Compound Annual Growth Rate (CAGR)

10.2.2.5. Regional Bifurcation

10.2.2.5.1. North America

10.2.2.5.1.1. Market Estimation, 2015 - 2021

10.2.2.5.1.2. Market Forecast, 2022 - 2030

10.2.2.5.2. Europe

10.2.2.5.2.1. Market Estimation, 2015 - 2021

10.2.2.5.2.2. Market Forecast, 2022 - 2030

10.2.2.5.3. Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 - 2021

10.2.2.5.3.2. Market Forecast, 2022 - 2030

10.2.2.5.4. Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 - 2021

10.2.2.5.4.2. Market Forecast, 2022 - 2030

10.2.2.5.5. Latin America

10.2.2.5.5.1. Market Estimation, 2015 - 2021

10.2.2.5.5.2. Market Forecast, 2022 - 2030

10.2.3. Cardiovascular

10.2.3.1. Definition

10.2.3.2. Market Estimation and Penetration, 2015 - 2021

10.2.3.3. Market Forecast, 2022 - 2030

10.2.3.4. Compound Annual Growth Rate (CAGR)

10.2.3.5. Regional Bifurcation

10.2.3.5.1. North America

10.2.3.5.1.1. Market Estimation, 2015 - 2021

10.2.3.5.1.2. Market Forecast, 2022 - 2030

10.2.3.5.2. Europe

10.2.3.5.2.1. Market Estimation, 2015 - 2021

10.2.3.5.2.2. Market Forecast, 2022 - 2030

10.2.3.5.3. Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 - 2021

10.2.3.5.3.2. Market Forecast, 2022 - 2030

10.2.3.5.4. Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 - 2021

10.2.3.5.4.2. Market Forecast, 2022 - 2030

10.2.3.5.5. Latin America

10.2.3.5.5.1. Market Estimation, 2015 - 2021

10.2.3.5.5.2. Market Forecast, 2022 - 2030

10.2.4. Dermatology

10.2.4.1. Definition

10.2.4.2. Market Estimation and Penetration, 2015 - 2021

10.2.4.3. Market Forecast, 2022 - 2030

10.2.4.4. Compound Annual Growth Rate (CAGR)

10.2.4.5. Regional Bifurcation

10.2.4.5.1. North America

10.2.4.5.1.1. Market Estimation, 2015 - 2021

10.2.4.5.1.2. Market Forecast, 2022 - 2030

10.2.4.5.2. Europe

10.2.4.5.2.1. Market Estimation, 2015 - 2021

10.2.4.5.2.2. Market Forecast, 2022 - 2030

10.2.4.5.3. Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 - 2021

10.2.4.5.3.2. Market Forecast, 2022 - 2030

10.2.4.5.4. Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 - 2021

10.2.4.5.4.2. Market Forecast, 2022 - 2030

10.2.4.5.5. Latin America

10.2.4.5.5.1. Market Estimation, 2015 - 2021

10.2.4.5.5.2. Market Forecast, 2022 - 2030

10.2.5. Mucoskeletal

10.2.5.1. Definition

10.2.5.2. Market Estimation and Penetration, 2015 - 2021

10.2.5.3. Market Forecast, 2022 - 2030

10.2.5.4. Compound Annual Growth Rate (CAGR)

10.2.5.5. Regional Bifurcation

10.2.5.5.1. North America

10.2.5.5.1.1. Market Estimation, 2015 - 2021

10.2.5.5.1.2. Market Forecast, 2022 - 2030

10.2.5.5.2. Europe

10.2.5.5.2.1. Market Estimation, 2015 - 2021

10.2.5.5.2.2. Market Forecast, 2022 - 2030

10.2.5.5.3. Asia Pacific

10.2.5.5.3.1. Market Estimation, 2015 - 2021

10.2.5.5.3.2. Market Forecast, 2022 - 2030

10.2.5.5.4. Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2015 - 2021

10.2.5.5.4.2. Market Forecast, 2022 - 2030

10.2.5.5.5. Latin America

10.2.5.5.5.1. Market Estimation, 2015 - 2021

10.2.5.5.5.2. Market Forecast, 2022 - 2030

10.2.6. Ophthalmology

10.2.6.1. Definition

10.2.6.2. Market Estimation and Penetration, 2015 - 2021

10.2.6.3. Market Forecast, 2022 - 2030

10.2.6.4. Compound Annual Growth Rate (CAGR)

10.2.6.5. Regional Bifurcation

10.2.6.5.1. North America

10.2.6.5.1.1. Market Estimation, 2015 - 2021

10.2.6.5.1.2. Market Forecast, 2022 - 2030

10.2.6.5.2. Europe

10.2.6.5.2.1. Market Estimation, 2015 - 2021

10.2.6.5.2.2. Market Forecast, 2022 - 2030

10.2.6.5.3. Asia Pacific

10.2.6.5.3.1. Market Estimation, 2015 - 2021

10.2.6.5.3.2. Market Forecast, 2022 - 2030

10.2.6.5.4. Middle East and Africa

10.2.6.5.4.1. Market Estimation, 2015 - 2021

10.2.6.5.4.2. Market Forecast, 2022 - 2030

10.2.6.5.5. Latin America

10.2.6.5.5.1. Market Estimation, 2015 - 2021

10.2.6.5.5.2. Market Forecast, 2022 - 2030

10.2.7. Neurology

10.2.7.1. Definition

10.2.7.2. Market Estimation and Penetration, 2015 - 2021

10.2.7.3. Market Forecast, 2022 - 2030

10.2.7.4. Compound Annual Growth Rate (CAGR)

10.2.7.5. Regional Bifurcation

10.2.7.5.1. North America

10.2.7.5.1.1. Market Estimation, 2015 - 2021

10.2.7.5.1.2. Market Forecast, 2022 - 2030

10.2.7.5.2. Europe

10.2.7.5.2.1. Market Estimation, 2015 - 2021

10.2.7.5.2.2. Market Forecast, 2022 - 2030

10.2.7.5.3. Asia Pacific

10.2.7.5.3.1. Market Estimation, 2015 - 2021

10.2.7.5.3.2. Market Forecast, 2022 - 2030

10.2.7.5.4. Middle East and Africa

10.2.7.5.4.1. Market Estimation, 2015 - 2021

10.2.7.5.4.2. Market Forecast, 2022 - 2030

10.2.7.5.5. Latin America

10.2.7.5.5.1. Market Estimation, 2015 - 2021

10.2.7.5.5.2. Market Forecast, 2022 - 2030

10.2.8. Wound Healing

10.2.8.1. Definition

10.2.8.2. Market Estimation and Penetration, 2015 - 2021

10.2.8.3. Market Forecast, 2022 - 2030

10.2.8.4. Compound Annual Growth Rate (CAGR)

10.2.8.5. Regional Bifurcation

10.2.8.5.1. North America

10.2.8.5.1.1. Market Estimation, 2015 - 2021

10.2.8.5.1.2. Market Forecast, 2022 - 2030

10.2.8.5.2. Europe

10.2.8.5.2.1. Market Estimation, 2015 - 2021

10.2.8.5.2.2. Market Forecast, 2022 - 2030

10.2.8.5.3. Asia Pacific

10.2.8.5.3.1. Market Estimation, 2015 - 2021

10.2.8.5.3.2. Market Forecast, 2022 - 2030

10.2.8.5.4. Middle East and Africa

10.2.8.5.4.1. Market Estimation, 2015 - 2021

10.2.8.5.4.2. Market Forecast, 2022 - 2030

10.2.8.5.5. Latin America

10.2.8.5.5.1. Market Estimation, 2015 - 2021

10.2.8.5.5.2. Market Forecast, 2022 - 2030

10.2.9. Others

10.2.9.1. Definition

10.2.9.2. Market Estimation and Penetration, 2015 - 2021

10.2.9.3. Market Forecast, 2022 - 2030

10.2.9.4. Compound Annual Growth Rate (CAGR)

10.2.9.5. Regional Bifurcation

10.2.9.5.1. North America

10.2.9.5.1.1. Market Estimation, 2015 - 2021

10.2.9.5.1.2. Market Forecast, 2022 - 2030

10.2.9.5.2. Europe

10.2.9.5.2.1. Market Estimation, 2015 - 2021

10.2.9.5.2.2. Market Forecast, 2022 - 2030

10.2.9.5.3. Asia Pacific

10.2.9.5.3.1. Market Estimation, 2015 - 2021

10.2.9.5.3.2. Market Forecast, 2022 - 2030

10.2.9.5.4. Middle East and Africa

10.2.9.5.4.1. Market Estimation, 2015 - 2021

10.2.9.5.4.2. Market Forecast, 2022 - 2030

10.2.9.5.5. Latin America

10.2.9.5.5.1. Market Estimation, 2015 - 2021

10.2.9.5.5.2. Market Forecast, 2022 - 2030

10.3. Key Segment for Channeling Investments

10.3.1. By Therapeutic Areas

11. North AmericaÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

11.1. Overview

11.1.1. North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

11.2. North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

11.2.1. Preclinical

11.2.2. Phase I

11.2.3. Phase II

11.2.4. Phase III

11.3. North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

11.3.1. Cell therapy

11.3.1.1. Autologous

11.3.1.2. Allogeneic

11.3.1.3. Both

11.3.2. Gene therapy

11.3.3. Tissue Engineering and Biomaterials

11.3.4. Cellular Scaffold

11.3.5. Others

11.4. North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

11.4.1. Autoimmune

11.4.2. Oncology

11.4.3. Cardiovascular

11.4.4. Dermatology

11.4.5. Mucoskeletal

11.4.6. Ophthalmology

11.4.7. Neurology

11.4.8. Wound Healing

11.4.9. Others

11.5. North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

11.5.1. U.S

11.5.1.1. U.SÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

11.5.1.1.1. Preclinical

11.5.1.1.2. Phase I

11.5.1.1.3. Phase II

11.5.1.1.4. Phase III

11.5.1.2. U.SÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

11.5.1.2.1. Cell therapy

11.5.1.2.1.1. Autologous

11.5.1.2.1.2. Allogeneic

11.5.1.2.1.3. Both

11.5.1.2.2. Gene therapy

11.5.1.2.3. Tissue Engineering and Biomaterials

11.5.1.2.4. Cellular Scaffold

11.5.1.2.5. Others

11.5.1.3. U.SÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

11.5.1.3.1. Autoimmune

11.5.1.3.2. Oncology

11.5.1.3.3. Cardiovascular

11.5.1.3.4. Dermatology

11.5.1.3.5. Mucoskeletal

11.5.1.3.6. Ophthalmology

11.5.1.3.7. Neurology

11.5.1.3.8. Wound Healing

11.5.1.3.9. Others

11.5.2. Canada

11.5.2.1. CanadaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

11.5.2.1.1. Preclinical

11.5.2.1.2. Phase I

11.5.2.1.3. Phase II

11.5.2.1.4. Phase III

11.5.2.2. CanadaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

11.5.2.2.1. Cell therapy

11.5.2.2.1.1. Autologous

11.5.2.2.1.2. Allogeneic

11.5.2.2.1.3. Both

11.5.2.2.2. Gene therapy

11.5.2.2.3. Tissue Engineering and Biomaterials

11.5.2.2.4. Cellular Scaffold

11.5.2.2.5. Others

11.5.2.3. CanadaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

11.5.2.3.1. Autoimmune

11.5.2.3.2. Oncology

11.5.2.3.3. Cardiovascular

11.5.2.3.4. Dermatology

11.5.2.3.5. Mucoskeletal

11.5.2.3.6. Ophthalmology

11.5.2.3.7. Neurology

11.5.2.3.8. Wound Healing

11.5.2.3.9. Others

11.5.3. Mexico

11.5.3.1. MexicoÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

11.5.3.1.1. Preclinical

11.5.3.1.2. Phase I

11.5.3.1.3. Phase II

11.5.3.1.4. Phase III

11.5.3.2. MexicoÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

11.5.3.2.1. Cell therapy

11.5.3.2.1.1. Autologous

11.5.3.2.1.2. Allogeneic

11.5.3.2.1.3. Both

11.5.3.2.2. Gene therapy

11.5.3.2.3. Tissue Engineering and Biomaterials

11.5.3.2.4. Cellular Scaffold

11.5.3.2.5. Others

11.5.3.3. MexicoÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

11.5.3.3.1. Autoimmune

11.5.3.3.2. Oncology

11.5.3.3.3. Cardiovascular

11.5.3.3.4. Dermatology

11.5.3.3.5. Mucoskeletal

11.5.3.3.6. Ophthalmology

11.5.3.3.7. Neurology

11.5.3.3.8. Wound Healing

11.5.3.3.9. Others

11.5.4. Rest of North America

11.5.4.1. Rest of North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

11.5.4.1.1. Preclinical

11.5.4.1.2. Phase I

11.5.4.1.3. Phase II

11.5.4.1.4. Phase III

11.5.4.2. Rest of North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

11.5.4.2.1. Cell therapy

11.5.4.2.1.1. Autologous

11.5.4.2.1.2. Allogeneic

11.5.4.2.1.3. Both

11.5.4.2.2. Gene therapy

11.5.4.2.3. Tissue Engineering and Biomaterials

11.5.4.2.4. Cellular Scaffold

11.5.4.2.5. Others

11.5.4.3. Rest of North AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

11.5.4.3.1. Autoimmune

11.5.4.3.2. Oncology

11.5.4.3.3. Cardiovascular

11.5.4.3.4. Dermatology

11.5.4.3.5. Mucoskeletal

11.5.4.3.6. Ophthalmology

11.5.4.3.7. Neurology

11.5.4.3.8. Wound Healing

11.5.4.3.9. Others

11.6. Key Segment for Channeling Investments

11.6.1. By Country

11.6.2. By Clinical Trial Phase

11.6.3. By Offerings

11.6.4. By Therapeutic Areas

12. EuropeÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.1.1. EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

12.2. EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.2.1. Preclinical

12.2.2. Phase I

12.2.3. Phase II

12.2.4. Phase III

12.3. EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.3.1. Cell therapy

12.3.1.1. Autologous

12.3.1.2. Allogeneic

12.3.1.3. Both

12.3.2. Gene therapy

12.3.3. Tissue Engineering and Biomaterials

12.3.4. Cellular Scaffold

12.3.5. Others

12.4. EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.4.1. Autoimmune

12.4.2. Oncology

12.4.3. Cardiovascular

12.4.4. Dermatology

12.4.5. Mucoskeletal

12.4.6. Ophthalmology

12.4.7. Neurology

12.4.8. Wound Healing

12.4.9. Others

12.5. EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

12.5.1. France

12.5.1.1. FranceÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.1.1.1. Preclinical

12.5.1.1.2. Phase I

12.5.1.1.3. Phase II

12.5.1.1.4. Phase III

12.5.1.2. FranceÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.1.2.1. Cell therapy

12.5.1.2.1.1. Autologous

12.5.1.2.1.2. Allogeneic

12.5.1.2.1.3. Both

12.5.1.2.2. Gene therapy

12.5.1.2.3. Tissue Engineering and Biomaterials

12.5.1.2.4. Cellular Scaffold

12.5.1.2.5. Others

12.5.1.3. FranceÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.1.3.1. Autoimmune

12.5.1.3.2. Oncology

12.5.1.3.3. Cardiovascular

12.5.1.3.4. Dermatology

12.5.1.3.5. Mucoskeletal

12.5.1.3.6. Ophthalmology

12.5.1.3.7. Neurology

12.5.1.3.8. Wound Healing

12.5.1.3.9. Others

12.5.2. The UK

12.5.2.1. The UKÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.2.1.1. Preclinical

12.5.2.1.2. Phase I

12.5.2.1.3. Phase II

12.5.2.1.4. Phase III

12.5.2.2. The UKÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.2.2.1. Cell therapy

12.5.2.2.1.1. Autologous

12.5.2.2.1.2. Allogeneic

12.5.2.2.1.3. Both

12.5.2.2.2. Gene therapy

12.5.2.2.3. Tissue Engineering and Biomaterials

12.5.2.2.4. Cellular Scaffold

12.5.2.2.5. Others

12.5.2.3. The UKÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.2.3.1. Autoimmune

12.5.2.3.2. Oncology

12.5.2.3.3. Cardiovascular

12.5.2.3.4. Dermatology

12.5.2.3.5. Mucoskeletal

12.5.2.3.6. Ophthalmology

12.5.2.3.7. Neurology

12.5.2.3.8. Wound Healing

12.5.2.3.9. Others

12.5.3. Spain

12.5.3.1. SpainÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.3.1.1. Preclinical

12.5.3.1.2. Phase I

12.5.3.1.3. Phase II

12.5.3.1.4. Phase III

12.5.3.2. SpainÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.3.2.1. Cell therapy

12.5.3.2.1.1. Autologous

12.5.3.2.1.2. Allogeneic

12.5.3.2.1.3. Both

12.5.3.2.2. Gene therapy

12.5.3.2.3. Tissue Engineering and Biomaterials

12.5.3.2.4. Cellular Scaffold

12.5.3.2.5. Others

12.5.3.3. SpainÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.3.3.1. Autoimmune

12.5.3.3.2. Oncology

12.5.3.3.3. Cardiovascular

12.5.3.3.4. Dermatology

12.5.3.3.5. Mucoskeletal

12.5.3.3.6. Ophthalmology

12.5.3.3.7. Neurology

12.5.3.3.8. Wound Healing

12.5.3.3.9. Others

12.5.4. Germany

12.5.4.1. GermanyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.4.1.1. Preclinical

12.5.4.1.2. Phase I

12.5.4.1.3. Phase II

12.5.4.1.4. Phase III

12.5.4.2. GermanyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.4.2.1. Cell therapy

12.5.4.2.1.1. Autologous

12.5.4.2.1.2. Allogeneic

12.5.4.2.1.3. Both

12.5.4.2.2. Gene therapy

12.5.4.2.3. Tissue Engineering and Biomaterials

12.5.4.2.4. Cellular Scaffold

12.5.4.2.5. Others

12.5.4.3. GermanyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.4.3.1. Autoimmune

12.5.4.3.2. Oncology

12.5.4.3.3. Cardiovascular

12.5.4.3.4. Dermatology

12.5.4.3.5. Mucoskeletal

12.5.4.3.6. Ophthalmology

12.5.4.3.7. Neurology

12.5.4.3.8. Wound Healing

12.5.4.3.9. Others

12.5.5. Italy

12.5.5.1. ItalyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.5.1.1. Preclinical

12.5.5.1.2. Phase I

12.5.5.1.3. Phase II

12.5.5.1.4. Phase III

12.5.5.2. ItalyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.5.2.1. Cell therapy

12.5.5.2.1.1. Autologous

12.5.5.2.1.2. Allogeneic

12.5.5.2.1.3. Both

12.5.5.2.2. Gene therapy

12.5.5.2.3. Tissue Engineering and Biomaterials

12.5.5.2.4. Cellular Scaffold

12.5.5.2.5. Others

12.5.5.3. ItalyÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.5.3.1. Autoimmune

12.5.5.3.2. Oncology

12.5.5.3.3. Cardiovascular

12.5.5.3.4. Dermatology

12.5.5.3.5. Mucoskeletal

12.5.5.3.6. Ophthalmology

12.5.5.3.7. Neurology

12.5.5.3.8. Wound Healing

12.5.5.3.9. Others

12.5.6. Nordic Countries

12.5.6.1. Nordic CountriesÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.6.1.1. Preclinical

12.5.6.1.2. Phase I

12.5.6.1.3. Phase II

12.5.6.1.4. Phase III

12.5.6.2. Nordic CountriesÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.6.2.1. Cell therapy

12.5.6.2.1.1. Autologous

12.5.6.2.1.2. Allogeneic

12.5.6.2.1.3. Both

12.5.6.2.2. Gene therapy

12.5.6.2.3. Tissue Engineering and Biomaterials

12.5.6.2.4. Cellular Scaffold

12.5.6.2.5. Others

12.5.6.3. Nordic CountriesÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.6.3.1. Autoimmune

12.5.6.3.2. Oncology

12.5.6.3.3. Cardiovascular

12.5.6.3.4. Dermatology

12.5.6.3.5. Mucoskeletal

12.5.6.3.6. Ophthalmology

12.5.6.3.7. Neurology

12.5.6.3.8. Wound Healing

12.5.6.3.9. Others

12.5.6.4. Nordic CountriesÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

12.5.6.4.1. Denmark

12.5.6.4.2. Finland

12.5.6.4.3. Iceland

12.5.6.4.4. Sweden

12.5.6.4.5. Norway

12.5.7. Benelux Union

12.5.7.1. Benelux UnionÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.7.1.1. Preclinical

12.5.7.1.2. Phase I

12.5.7.1.3. Phase II

12.5.7.1.4. Phase III

12.5.7.2. Benelux UnionÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.7.2.1. Cell therapy

12.5.7.2.1.1. Autologous

12.5.7.2.1.2. Allogeneic

12.5.7.2.1.3. Both

12.5.7.2.2. Gene therapy

12.5.7.2.3. Tissue Engineering and Biomaterials

12.5.7.2.4. Cellular Scaffold

12.5.7.2.5. Others

12.5.7.3. Benelux UnionÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.7.3.1. Autoimmune

12.5.7.3.2. Oncology

12.5.7.3.3. Cardiovascular

12.5.7.3.4. Dermatology

12.5.7.3.5. Mucoskeletal

12.5.7.3.6. Ophthalmology

12.5.7.3.7. Neurology

12.5.7.3.8. Wound Healing

12.5.7.3.9. Others

12.5.7.4. Benelux UnionÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

12.5.7.4.1. Belgium

12.5.7.4.2. The Netherlands

12.5.7.4.3. Luxembourg

12.5.8. Rest of Europe

12.5.8.1. Rest of EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

12.5.8.1.1. Preclinical

12.5.8.1.2. Phase I

12.5.8.1.3. Phase II

12.5.8.1.4. Phase III

12.5.8.2. Rest of EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

12.5.8.2.1. Cell therapy

12.5.8.2.1.1. Autologous

12.5.8.2.1.2. Allogeneic

12.5.8.2.1.3. Both

12.5.8.2.2. Gene therapy

12.5.8.2.3. Tissue Engineering and Biomaterials

12.5.8.2.4. Cellular Scaffold

12.5.8.2.5. Others

12.5.8.3. Rest of EuropeÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

12.5.8.3.1. Autoimmune

12.5.8.3.2. Oncology

12.5.8.3.3. Cardiovascular

12.5.8.3.4. Dermatology

12.5.8.3.5. Mucoskeletal

12.5.8.3.6. Ophthalmology

12.5.8.3.7. Neurology

12.5.8.3.8. Wound Healing

12.5.8.3.9. Others

12.6. Key Segment for Channeling Investments

12.6.1. By Country

12.6.2. By Clinical Trial Phase

12.6.3. By Offerings

12.6.4. By Therapeutic Areas

13. Asia PacificÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

13.2. Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.2.1. Preclinical

13.2.2. Phase I

13.2.3. Phase II

13.2.4. Phase III

13.3. Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.3.1. Cell therapy

13.3.1.1. Autologous

13.3.1.2. Allogeneic

13.3.1.3. Both

13.3.2. Gene therapy

13.3.3. Tissue Engineering and Biomaterials

13.3.4. Cellular Scaffold

13.3.5. Others

13.4. Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.4.1. Autoimmune

13.4.2. Oncology

13.4.3. Cardiovascular

13.4.4. Dermatology

13.4.5. Mucoskeletal

13.4.6. Ophthalmology

13.4.7. Neurology

13.4.8. Wound Healing

13.4.9. Others

13.5. Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

13.5.1. China

13.5.1.1. ChinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.1.1.1. Preclinical

13.5.1.1.2. Phase I

13.5.1.1.3. Phase II

13.5.1.1.4. Phase III

13.5.1.2. ChinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.1.2.1. Cell therapy

13.5.1.2.1.1. Autologous

13.5.1.2.1.2. Allogeneic

13.5.1.2.1.3. Both

13.5.1.2.2. Gene therapy

13.5.1.2.3. Tissue Engineering and Biomaterials

13.5.1.2.4. Cellular Scaffold

13.5.1.2.5. Others

13.5.1.3. ChinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.1.3.1. Autoimmune

13.5.1.3.2. Oncology

13.5.1.3.3. Cardiovascular

13.5.1.3.4. Dermatology

13.5.1.3.5. Mucoskeletal

13.5.1.3.6. Ophthalmology

13.5.1.3.7. Neurology

13.5.1.3.8. Wound Healing

13.5.1.3.9. Others

13.5.2. Japan

13.5.2.1. JapanÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.2.1.1. Preclinical

13.5.2.1.2. Phase I

13.5.2.1.3. Phase II

13.5.2.1.4. Phase III

13.5.2.2. JapanÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.2.2.1. Cell therapy

13.5.2.2.1.1. Autologous

13.5.2.2.1.2. Allogeneic

13.5.2.2.1.3. Both

13.5.2.2.2. Gene therapy

13.5.2.2.3. Tissue Engineering and Biomaterials

13.5.2.2.4. Cellular Scaffold

13.5.2.2.5. Others

13.5.2.3. JapanÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.2.3.1. Autoimmune

13.5.2.3.2. Oncology

13.5.2.3.3. Cardiovascular

13.5.2.3.4. Dermatology

13.5.2.3.5. Mucoskeletal

13.5.2.3.6. Ophthalmology

13.5.2.3.7. Neurology

13.5.2.3.8. Wound Healing

13.5.2.3.9. Others

13.5.3. India

13.5.3.1. IndiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.3.1.1. Preclinical

13.5.3.1.2. Phase I

13.5.3.1.3. Phase II

13.5.3.1.4. Phase III

13.5.3.2. IndiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.3.2.1. Cell therapy

13.5.3.2.1.1. Autologous

13.5.3.2.1.2. Allogeneic

13.5.3.2.1.3. Both

13.5.3.2.2. Gene therapy

13.5.3.2.3. Tissue Engineering and Biomaterials

13.5.3.2.4. Cellular Scaffold

13.5.3.2.5. Others

13.5.3.3. IndiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.3.3.1. Autoimmune

13.5.3.3.2. Oncology

13.5.3.3.3. Cardiovascular

13.5.3.3.4. Dermatology

13.5.3.3.5. Mucoskeletal

13.5.3.3.6. Ophthalmology

13.5.3.3.7. Neurology

13.5.3.3.8. Wound Healing

13.5.3.3.9. Others

13.5.4. New Zealand

13.5.4.1. New ZealandÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.4.1.1. Preclinical

13.5.4.1.2. Phase I

13.5.4.1.3. Phase II

13.5.4.1.4. Phase III

13.5.4.2. New ZealandÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.4.2.1. Cell therapy

13.5.4.2.1.1. Autologous

13.5.4.2.1.2. Allogeneic

13.5.4.2.1.3. Both

13.5.4.2.2. Gene therapy

13.5.4.2.3. Tissue Engineering and Biomaterials

13.5.4.2.4. Cellular Scaffold

13.5.4.2.5. Others

13.5.4.3. New ZealandÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.4.3.1. Autoimmune

13.5.4.3.2. Oncology

13.5.4.3.3. Cardiovascular

13.5.4.3.4. Dermatology

13.5.4.3.5. Mucoskeletal

13.5.4.3.6. Ophthalmology

13.5.4.3.7. Neurology

13.5.4.3.8. Wound Healing

13.5.4.3.9. Others

13.5.5. Australia

13.5.5.1. AustraliaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.5.1.1. Preclinical

13.5.5.1.2. Phase I

13.5.5.1.3. Phase II

13.5.5.1.4. Phase III

13.5.5.2. AustraliaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.5.2.1. Cell therapy

13.5.5.2.1.1. Autologous

13.5.5.2.1.2. Allogeneic

13.5.5.2.1.3. Both

13.5.5.2.2. Gene therapy

13.5.5.2.3. Tissue Engineering and Biomaterials

13.5.5.2.4. Cellular Scaffold

13.5.5.2.5. Others

13.5.5.3. AustraliaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.5.3.1. Autoimmune

13.5.5.3.2. Oncology

13.5.5.3.3. Cardiovascular

13.5.5.3.4. Dermatology

13.5.5.3.5. Mucoskeletal

13.5.5.3.6. Ophthalmology

13.5.5.3.7. Neurology

13.5.5.3.8. Wound Healing

13.5.5.3.9. Others

13.5.6. South Korea

13.5.6.1. South KoreaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.6.1.1. Preclinical

13.5.6.1.2. Phase I

13.5.6.1.3. Phase II

13.5.6.1.4. Phase III

13.5.6.2. South KoreaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.6.2.1. Cell therapy

13.5.6.2.1.1. Autologous

13.5.6.2.1.2. Allogeneic

13.5.6.2.1.3. Both

13.5.6.2.2. Gene therapy

13.5.6.2.3. Tissue Engineering and Biomaterials

13.5.6.2.4. Cellular Scaffold

13.5.6.2.5. Others

13.5.6.3. South KoreaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.6.3.1. Autoimmune

13.5.6.3.2. Oncology

13.5.6.3.3. Cardiovascular

13.5.6.3.4. Dermatology

13.5.6.3.5. Mucoskeletal

13.5.6.3.6. Ophthalmology

13.5.6.3.7. Neurology

13.5.6.3.8. Wound Healing

13.5.6.3.9. Others

13.5.7. Southeast Asia

13.5.7.1. Southeast AsiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.7.1.1. Preclinical

13.5.7.1.2. Phase I

13.5.7.1.3. Phase II

13.5.7.1.4. Phase III

13.5.7.2. Southeast AsiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.7.2.1. Cell therapy

13.5.7.2.1.1. Autologous

13.5.7.2.1.2. Allogeneic

13.5.7.2.1.3. Both

13.5.7.2.2. Gene therapy

13.5.7.2.3. Tissue Engineering and Biomaterials

13.5.7.2.4. Cellular Scaffold

13.5.7.2.5. Others

13.5.7.3. Southeast AsiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.7.3.1. Autoimmune

13.5.7.3.2. Oncology

13.5.7.3.3. Cardiovascular

13.5.7.3.4. Dermatology

13.5.7.3.5. Mucoskeletal

13.5.7.3.6. Ophthalmology

13.5.7.3.7. Neurology

13.5.7.3.8. Wound Healing

13.5.7.3.9. Others

13.5.7.4. Southeast AsiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

13.5.7.4.1. Indonesia

13.5.7.4.2. Thailand

13.5.7.4.3. Malaysia

13.5.7.4.4. Singapore

13.5.7.4.5. Rest of Southeast Asia

13.5.8. Rest of Asia Pacific

13.5.8.1. Rest of Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

13.5.8.1.1. Preclinical

13.5.8.1.2. Phase I

13.5.8.1.3. Phase II

13.5.8.1.4. Phase III

13.5.8.2. Rest of Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

13.5.8.2.1. Cell therapy

13.5.8.2.1.1. Autologous

13.5.8.2.1.2. Allogeneic

13.5.8.2.1.3. Both

13.5.8.2.2. Gene therapy

13.5.8.2.3. Tissue Engineering and Biomaterials

13.5.8.2.4. Cellular Scaffold

13.5.8.2.5. Others

13.5.8.3. Rest of Asia PacificÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

13.5.8.3.1. Autoimmune

13.5.8.3.2. Oncology

13.5.8.3.3. Cardiovascular

13.5.8.3.4. Dermatology

13.5.8.3.5. Mucoskeletal

13.5.8.3.6. Ophthalmology

13.5.8.3.7. Neurology

13.5.8.3.8. Wound Healing

13.5.8.3.9. Others

13.6. Key Segment for Channeling Investments

13.6.1. By Country

13.6.2. By Clinical Trial Phase

13.6.3. By Offerings

13.6.4. By Therapeutic Areas

14. Middle East and AfricaÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Middle East and AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

14.2. Middle East and AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.2.1. Preclinical

14.2.2. Phase I

14.2.3. Phase II

14.2.4. Phase III

14.3. Middle East and AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.3.1. Cell therapy

14.3.1.1. Autologous

14.3.1.2. Allogeneic

14.3.1.3. Both

14.3.2. Gene therapy

14.3.3. Tissue Engineering and Biomaterials

14.3.4. Cellular Scaffold

14.3.5. Others

14.4. Middle East and AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.4.1. Autoimmune

14.4.2. Oncology

14.4.3. Cardiovascular

14.4.4. Dermatology

14.4.5. Mucoskeletal

14.4.6. Ophthalmology

14.4.7. Neurology

14.4.8. Wound Healing

14.4.9. Others

14.5. Middle East and AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

14.5.1. Saudi Arabia

14.5.1.1. Saudi ArabiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.1.1.1. Preclinical

14.5.1.1.2. Phase I

14.5.1.1.3. Phase II

14.5.1.1.4. Phase III

14.5.1.2. Saudi ArabiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.1.2.1. Cell therapy

14.5.1.2.1.1. Autologous

14.5.1.2.1.2. Allogeneic

14.5.1.2.1.3. Both

14.5.1.2.2. Gene therapy

14.5.1.2.3. Tissue Engineering and Biomaterials

14.5.1.2.4. Cellular Scaffold

14.5.1.2.5. Others

14.5.1.3. Saudi ArabiaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.1.3.1. Autoimmune

14.5.1.3.2. Oncology

14.5.1.3.3. Cardiovascular

14.5.1.3.4. Dermatology

14.5.1.3.5. Mucoskeletal

14.5.1.3.6. Ophthalmology

14.5.1.3.7. Neurology

14.5.1.3.8. Wound Healing

14.5.1.3.9. Others

14.5.2. UAE

14.5.2.1. UAEÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.2.1.1. Preclinical

14.5.2.1.2. Phase I

14.5.2.1.3. Phase II

14.5.2.1.4. Phase III

14.5.2.2. UAEÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.2.2.1. Cell therapy

14.5.2.2.1.1. Autologous

14.5.2.2.1.2. Allogeneic

14.5.2.2.1.3. Both

14.5.2.2.2. Gene therapy

14.5.2.2.3. Tissue Engineering and Biomaterials

14.5.2.2.4. Cellular Scaffold

14.5.2.2.5. Others

14.5.2.3. UAEÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.2.3.1. Autoimmune

14.5.2.3.2. Oncology

14.5.2.3.3. Cardiovascular

14.5.2.3.4. Dermatology

14.5.2.3.5. Mucoskeletal

14.5.2.3.6. Ophthalmology

14.5.2.3.7. Neurology

14.5.2.3.8. Wound Healing

14.5.2.3.9. Others

14.5.3. Egypt

14.5.3.1. EgyptÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.3.1.1. Preclinical

14.5.3.1.2. Phase I

14.5.3.1.3. Phase II

14.5.3.1.4. Phase III

14.5.3.2. EgyptÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.3.2.1. Cell therapy

14.5.3.2.1.1. Autologous

14.5.3.2.1.2. Allogeneic

14.5.3.2.1.3. Both

14.5.3.2.2. Gene therapy

14.5.3.2.3. Tissue Engineering and Biomaterials

14.5.3.2.4. Cellular Scaffold

14.5.3.2.5. Others

14.5.3.3. EgyptÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.3.3.1. Autoimmune

14.5.3.3.2. Oncology

14.5.3.3.3. Cardiovascular

14.5.3.3.4. Dermatology

14.5.3.3.5. Mucoskeletal

14.5.3.3.6. Ophthalmology

14.5.3.3.7. Neurology

14.5.3.3.8. Wound Healing

14.5.3.3.9. Others

14.5.4. Kuwait

14.5.4.1. KuwaitÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.4.1.1. Preclinical

14.5.4.1.2. Phase I

14.5.4.1.3. Phase II

14.5.4.1.4. Phase III

14.5.4.2. KuwaitÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.4.2.1. Cell therapy

14.5.4.2.1.1. Autologous

14.5.4.2.1.2. Allogeneic

14.5.4.2.1.3. Both

14.5.4.2.2. Gene therapy

14.5.4.2.3. Tissue Engineering and Biomaterials

14.5.4.2.4. Cellular Scaffold

14.5.4.2.5. Others

14.5.4.3. KuwaitÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.4.3.1. Autoimmune

14.5.4.3.2. Oncology

14.5.4.3.3. Cardiovascular

14.5.4.3.4. Dermatology

14.5.4.3.5. Mucoskeletal

14.5.4.3.6. Ophthalmology

14.5.4.3.7. Neurology

14.5.4.3.8. Wound Healing

14.5.4.3.9. Others

14.5.5. South Africa

14.5.5.1. South AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.5.1.1. Preclinical

14.5.5.1.2. Phase I

14.5.5.1.3. Phase II

14.5.5.1.4. Phase III

14.5.5.2. South AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.5.2.1. Cell therapy

14.5.5.2.1.1. Autologous

14.5.5.2.1.2. Allogeneic

14.5.5.2.1.3. Both

14.5.5.2.2. Gene therapy

14.5.5.2.3. Tissue Engineering and Biomaterials

14.5.5.2.4. Cellular Scaffold

14.5.5.2.5. Others

14.5.5.3. South AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.5.3.1. Autoimmune

14.5.5.3.2. Oncology

14.5.5.3.3. Cardiovascular

14.5.5.3.4. Dermatology

14.5.5.3.5. Mucoskeletal

14.5.5.3.6. Ophthalmology

14.5.5.3.7. Neurology

14.5.5.3.8. Wound Healing

14.5.5.3.9. Others

14.5.6. Rest of Middle East & Africa

14.5.6.1. Rest of Middle East & AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

14.5.6.1.1. Preclinical

14.5.6.1.2. Phase I

14.5.6.1.3. Phase II

14.5.6.1.4. Phase III

14.5.6.2. Rest of Middle East & AfricaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

14.5.6.2.1. Cell therapy

14.5.6.2.1.1. Autologous

14.5.6.2.1.2. Allogeneic

14.5.6.2.1.3. Both

14.5.6.2.2. Gene therapy

14.5.6.2.3. Tissue Engineering and Biomaterials

14.5.6.2.4. Cellular Scaffold

14.5.6.2.5. Others

14.5.6.3. Rest of Middle East & Africa Â Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

14.5.6.3.1. Autoimmune

14.5.6.3.2. Oncology

14.5.6.3.3. Cardiovascular

14.5.6.3.4. Dermatology

14.5.6.3.5. Mucoskeletal

14.5.6.3.6. Ophthalmology

14.5.6.3.7. Neurology

14.5.6.3.8. Wound Healing

14.5.6.3.9. Others

14.6. Key Segment for Channeling Investments

14.6.1. By Country

14.6.2. By Clinical Trial Phase

14.6.3. By Offerings

14.6.4. By Therapeutic Areas

15. Latin AmericaÂ Regenerative MedicineÂ Market Analysis and Forecasts, 2022 - 2030

15.1. Overview

15.1.1. Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn)

15.2. Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

15.2.1. Preclinical

15.2.2. Phase I

15.2.3. Phase II

15.2.4. Phase III

15.3. Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

15.3.1. Cell therapy

15.3.1.1. Autologous

15.3.1.2. Allogeneic

15.3.1.3. Both

15.3.2. Gene therapy

15.3.3. Tissue Engineering and Biomaterials

15.3.4. Cellular Scaffold

15.3.5. Others

15.4. Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

15.4.1. Autoimmune

15.4.2. Oncology

15.4.3. Cardiovascular

15.4.4. Dermatology

15.4.5. Mucoskeletal

15.4.6. Ophthalmology

15.4.7. Neurology

15.4.8. Wound Healing

15.4.9. Others

15.5. Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Country

15.5.1. Brazil

15.5.1.1. BrazilÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

15.5.1.1.1. Preclinical

15.5.1.1.2. Phase I

15.5.1.1.3. Phase II

15.5.1.1.4. Phase III

15.5.1.2. BrazilÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

15.5.1.2.1. Cell therapy

15.5.1.2.1.1. Autologous

15.5.1.2.1.2. Allogeneic

15.5.1.2.1.3. Both

15.5.1.2.2. Gene therapy

15.5.1.2.3. Tissue Engineering and Biomaterials

15.5.1.2.4. Cellular Scaffold

15.5.1.2.5. Others

15.5.1.3. BrazilÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

15.5.1.3.1. Autoimmune

15.5.1.3.2. Oncology

15.5.1.3.3. Cardiovascular

15.5.1.3.4. Dermatology

15.5.1.3.5. Mucoskeletal

15.5.1.3.6. Ophthalmology

15.5.1.3.7. Neurology

15.5.1.3.8. Wound Healing

15.5.1.3.9. Others

15.5.2. Argentina

15.5.2.1. ArgentinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

15.5.2.1.1. Preclinical

15.5.2.1.2. Phase I

15.5.2.1.3. Phase II

15.5.2.1.4. Phase III

15.5.2.2. ArgentinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

15.5.2.2.1. Cell therapy

15.5.2.2.1.1. Autologous

15.5.2.2.1.2. Allogeneic

15.5.2.2.1.3. Both

15.5.2.2.2. Gene therapy

15.5.2.2.3. Tissue Engineering and Biomaterials

15.5.2.2.4. Cellular Scaffold

15.5.2.2.5. Others

15.5.2.3. ArgentinaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

15.5.2.3.1. Autoimmune

15.5.2.3.2. Oncology

15.5.2.3.3. Cardiovascular

15.5.2.3.4. Dermatology

15.5.2.3.5. Mucoskeletal

15.5.2.3.6. Ophthalmology

15.5.2.3.7. Neurology

15.5.2.3.8. Wound Healing

15.5.2.3.9. Others

15.5.3. Rest of Latin America

15.5.3.1. Rest of Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Clinical Trial Phase

15.5.3.1.1. Preclinical

15.5.3.1.2. Phase I

15.5.3.1.3. Phase II

15.5.3.1.4. Phase III

15.5.3.2. Rest of Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Offerings

15.5.3.2.1. Cell therapy

15.5.3.2.1.1. Autologous

15.5.3.2.1.2. Allogeneic

15.5.3.2.1.3. Both

15.5.3.2.2. Gene therapy

15.5.3.2.3. Tissue Engineering and Biomaterials

15.5.3.2.4. Cellular Scaffold

15.5.3.2.5. Others

15.5.3.3. Rest of Latin AmericaÂ Regenerative MedicineÂ Market Revenue (US$ Mn) and Forecasts, By Therapeutic Areas

15.5.3.3.1. Autoimmune

15.5.3.3.2. Oncology

15.5.3.3.3. Cardiovascular

15.5.3.3.4. Dermatology

15.5.3.3.5. Mucoskeletal

15.5.3.3.6. Ophthalmology

15.5.3.3.7. Neurology

15.5.3.3.8. Wound Healing

15.5.3.3.9. Others

15.6. Key Segment for Channeling Investments

15.6.1. By Country

15.6.2. By Clinical Trial Phase

15.6.3. By Offerings

15.6.4. By Therapeutic Areas

16. Competitive Benchmarking

16.1. Brand Benchmarking

16.2. Market Share Analysis, 2021

16.3. Global Presence and Growth Strategies

16.3.1. Mergers and Acquisitions

16.3.2. Product Launches

16.3.3. Investments Trends

16.3.4. R&D Initiatives

17. Player Profiles

17.1. 3M

17.1.1. Company Details

17.1.2. Company Overview

17.1.3. Product Offerings

17.1.4. Key Developments

17.1.5. Financial Analysis

17.1.6. SWOT Analysis

17.1.7. Business Strategies

17.2. ALLERGAN

17.2.1. Company Details

17.2.2. Company Overview

17.2.3. Product Offerings

17.2.4. Key Developments

17.2.5. Financial Analysis

17.2.6. SWOT Analysis

17.2.7. Business Strategies

17.3. Amgen, Inc.

17.3.1. Company Details

17.3.2. Company Overview

17.3.3. Product Offerings

17.3.4. Key Developments

17.3.5. Financial Analysis

17.3.6. SWOT Analysis

17.3.7. Business Strategies

17.4. Athersys, Inc.

17.4.1. Company Details

17.4.2. Company Overview

17.4.3. Product Offerings

17.4.4. Key Developments

17.4.5. Financial Analysis

17.4.6. SWOT Analysis

17.4.7. Business Strategies

17.5. Integra LifeSciences

17.5.1. Company Details

17.5.2. Company Overview

17.5.3. Product Offerings

17.5.4. Key Developments

17.5.5. Financial Analysis

17.5.6. SWOT Analysis

17.5.7. Business Strategies

17.6. Isto Biologics

17.6.1. Company Details

17.6.2. Company Overview

17.6.3. Product Offerings

17.6.4. Key Developments

17.6.5. Financial Analysis

17.6.6. SWOT Analysis

17.6.7. Business Strategies

17.7. Medtronic

17.7.1. Company Details

17.7.2. Company Overview

17.7.3. Product Offerings

17.7.4. Key Developments

17.7.5. Financial Analysis

17.7.6. SWOT Analysis

17.7.7. Business Strategies

17.8. Novartis AG

17.8.1. Company Details

17.8.2. Company Overview

17.8.3. Product Offerings

17.8.4. Key Developments

17.8.5. Financial Analysis

17.8.6. SWOT Analysis

17.8.7. Business Strategies

17.9. Organogenesis Inc.

17.9.1. Company Details

17.9.2. Company Overview

17.9.3. Product Offerings

17.9.4. Key Developments

17.9.5. Financial Analysis

17.9.6. SWOT Analysis

17.9.7. Business Strategies

17.10. Sartorius AG

17.10.1. Company Details

17.10.2. Company Overview

17.10.3. Product Offerings

17.10.4. Key Developments

17.10.5. Financial Analysis

17.10.6. SWOT Analysis

17.10.7. Business Strategies

17.11. Spark Therapeutics, Inc.

17.11.1. Company Details

17.11.2. Company Overview

17.11.3. Product Offerings

17.11.4. Key Developments

17.11.5. Financial Analysis

17.11.6. SWOT Analysis

17.11.7. Business Strategies

17.12. Takeda Pharmaceutical Company Limited

17.12.1. Company Details

17.12.2. Company Overview

17.12.3. Product Offerings

17.12.4. Key Developments

17.12.5. Financial Analysis

17.12.6. SWOT Analysis

17.12.7. Business Strategies

17.13. XCELL BIOLOGIX

17.13.1. Company Details

17.13.2. Company Overview

17.13.3. Product Offerings

17.13.4. Key Developments

17.13.5. Financial Analysis

17.13.6. SWOT Analysis

17.13.7. Business Strategies

17.14. Zimmer Biomet

17.14.1. Company Details

17.14.2. Company Overview

17.14.3. Product Offerings

17.14.4. Key Developments

17.14.5. Financial Analysis

17.14.6. SWOT Analysis

17.14.7. Business Strategies

17.15. Other Market Participants

18. Key Findings

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

**Exclusive for Multi-User and Enterprise User.

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.

Prominent participants in our primary research process include:

Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

Reuters
Factiva
Bloomberg
One Source
Hoovers

Research Methodology

Key Inclusions

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Single users $4600

Multi users $8200

Global users $9100

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com